Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
LDL cholesterol is an important contributor to the risk of coronary heart disease, and its measurement is central to evaluating the effects of lipid-modifying therapies. Several ‘LDL-cholesterol’ assays exist but their methodologies differ, leading to between-assay heterogeneity in values of ‘LDL cholesterol’. We advocate the need for awareness of the potential implications.
Pacemaker therapy is inaccessible to most patients with bradycardia in Africa. Use of reconditioned pacemakers has been proposed as a safe, efficacious, and ethical means of delivering this therapy. A collaboration between PASCAR, Pace4Life, and Project My Heart Your Heart is working to address this deficit in health care in Africa.
Despite substantial advances, bona fide regeneration of the damaged human heart is still an unmet ambition. By extracting our current knowledge from developmental biology, animal models of heart regeneration, and clinical observations, we propose five hallmarks of cardiac regeneration and suggest a holistic approach to reconstituting human heart function.
Life expectancy around the world has increased steadily for nearly 200 years. This Focus Issue of Nature Reviews Cardiology features five insightful Review articles that describe numerous facets of the latest research on cardiovascular ageing.
The recent publication ofThe LancetCommission on pollution and health is a watershed moment for one of the greatest challenges to cardiovascular health. In this Comment article, we discuss the global burden of air pollution on cardiovascular health.
The Atrial fibrillation Better Care (ABC) pathway for integrated management provides a simple strategy (Avoid stroke, Better symptom management, and Cardiovascular and comorbidity risk reduction) that helps to improve awareness and detection, and reminds clinicians of the simple decision-making steps for management of patients with atrial fibrillation in a holistic approach.
Both rare and common genetic variants predict the onset of cardiovascular disease (CVD), but recent studies have provided compelling evidence that individuals who harbour variants that elevate their risk of CVD can substantially lower this risk by controlling lifestyle-related risk factors, such as smoking, diet, and physical activity.
Shared decision-making (SDM) between physicians and patients is a necessary element of care in hypertrophic cardiomyopathy (HCM), particularly for decisions concerning prophylactic implantable defibrillators to prevent sudden death; however, SDM has much less relevance in making eligibility versus disqualification decisions for competitive athletes with HCM.
Sharing of data from clinical trials provides the opportunity to improve the value and integrity of data analyses, but there are risks, and the primary duty for responsible reporting should reside with the investigators.
